Skip to content


  • Research article
  • Open Access
  • Open Peer Review


Contributed equally
BMC Cancer201818:325

  • Received: 4 August 2017
  • Accepted: 20 March 2018
  • Published:
Open Peer Review reports











  • KPNA7
  • Importin alpha 8
  • Nuclear transfer
  • Nuclear morphology
  • Cell proliferation
  • Mitosis


Eukaryotic cells are compartmentalized to contain distinct organelles such as the nucleus. The separation of the nucleus from the cytoplasm by the nuclear envelope forms a barrier across which large macromolecules, such as proteins, need to be transported. This allows the physical separation of transcription events in the nucleus and protein translation in the cytoplasm, thereby providing the cell an additional system for the regulation of protein function [1, 2]. The nucleocytoplasmic transport of proteins is carried out by specific transport machinery where proteins are shuttled in and out of the nucleus through the nuclear pore complexes (NPC) at the nuclear envelope [3]. In the classical protein import, karyopherin alpha (KPNA, also known as importin alpha) recognizes the protein containing a nuclear localization signal (NLS) [46]. The KPNA-cargo complex then binds to karyopherin beta 1 (KPNB1, also known as importin beta) that docks to the NPC and mediates the transport to the nucleus, where the cargo is released when the GTP-binding nuclear protein Ran (Ran-GTP) binds to KPNB1 [6, 7].

Defects in nuclear import, for instance due to abnormal function of members of the nuclear transport machinery, result in incorrect localization of proteins that might subsequently lead to a diversity of diseases, including cancer [1, 812]. For example, the tumor suppressor protein p53 has been shown to be inactivated in cancer due to a truncated form of KPNA that was incapable of transporting p53 into the nucleus, its proper location of action [13, 14]. Currently, the strongest evidence on the role of karyopherins in cancer pathogenesis comes from studies on KPNA2. KPNA2 is upregulated in a large variety of tumor types and its elevated expression is associated with an increased degree of malignancy, tumor spread and poor patient outcome [15, 16]. KPNA2 overexpression is already present in early lesions indicating that it is not merely a marker of advanced disease but actively participates in the pathogenesis process [15]. This notion is supported by functional studies where enhanced KPNA2 expression leads to increased cell proliferation and migration [15]. Other KPNAs have also been implicated in cancer. For example, KPNA4 was recently shown to promote the migration and metastatic potential of prostate cancer cells [17]. These data illustrate that alterations in nuclear transport are important players in cancer pathogenesis.

The karyopherins in the cells are vital to proper nuclear transport but their functional roles are even more diverse. They participate in the assembly of the mitotic spindle where the duplicated chromosomes are aligned during mitosis, and thereby ensure the fidelity of cell division [18, 19]. Karyopherins bind the spindle assembly factors (SAFs), keeping them inactive, and release them in an appropriate location near mitotic chromosomes thus preventing mislocalization of the spindle [19]. The release of SAFs is regulated by the differential concentration of Ran-GTP between the nucleus and cytoplasm, which is maintained by guanine nucleotide exchange factors (GEFs) in the nucleus and GTPase activating proteins (GAPs) in the cytoplasm [20]. The Ran-GTP gradient is also preserved around the chromatin after the dissociation of the nuclear envelope during mitosis [20]. Subsequent to chromosome separation, karyopherins are also involved in the reassembly of the nuclear envelope that consists of the inner and outer nuclear membranes and associated proteins, mainly lamins and the NPC proteins [18, 19, 21].

The human karyopherin alpha family consists of seven highly conserved members, with KPNA7 being the most recently identified, divergent and least studied member [22, 23]. KPNA7 is mainly expressed during early embryogenesis and in oocytes in different animals [2426] and has been identified as one of the target genes for the 7q21-22 amplicon in pancreatic cancer [27]. However, the precise function of KPNA7 in human cells remains elusive. In our previous work we pinpointed KPNA7 as a regulator of malignant properties in pancreatic cancer cells with high KPNA7 expression [28]. Here we extend these findings to show that even low KPNA7 expression plays an important role in the proliferation of both pancreatic and breast cancer cells. Furthermore, our data demonstrate that KPNA7 has a key role in the proper formation of the mitotic spindle and in the maintenance of nuclear morphology.


Cell lines

Hs700T, MIA PaCa-2 and SU.86.86 pancreatic cancer cell lines; MCF-7, T-47D, MDA-MB-231 and MDA-MB-453 breast cancer cell lines and hTERT-HPNE normal pancreas epithelial cell line were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cell lines were authenticated by genotyping and were grown under recommended culture conditions. The cells were regularly tested for Mycoplasma infection.

Gene expression analysis

Total RNA was extracted using RNeasy Mini kit (Qiagen, Hilden, Germany). Quantitative real-time PCR (qRT-PCR) was performed using the Roche LightCycler 2.0 instrument (Roche, Mannheim, Germany) with LightCycler® TaqMan® Master reaction mix (Roche). Universal Probe Library (Roche) probes and associated primers (Sigma Aldrich, St Louis, MO, USA) and Roche’s Reference Gene Assay for HPRT was utilized for normalization. All primer and probe sequences are listed in Additional file 1: Table S1.

Gene silencing

Four specific small interfering RNAs (siRNAs) against the KPNA7 gene were designed using the siRNA Selection Program of the Whitehead Institute, Cambridge, MA, USA and the siRNAs were obtained from Dharmacon (Lafayette, CO, USA). A pool containing an equal concentration of each of the four siRNAs was prepared. SMAD5 SMARTpool siRNA was acquired from Dharmacon. An siRNA targeting the firefly luciferase (LUC) gene (Sigma Aldrich) was used as a control in all transfections. Transfections were performed either on 24-well or 6-well plates using 10 nM siRNA and Interferin reagent (Polyplus-Transfection, San Marcos, CA, USA) as described previously [27]. The efficacy of the gene silencing was verified in each experiment using qRT-PCR. The number of cells plated per experiment are listed in Additional file 1: Table S2.

Cell growth and cell cycle analysis

For cell proliferation assays, the cells were seeded (for cell numbers see Additional file 1: Table S2) on a 24-well plate and transfected with KPNA7 or LUC siRNAs as described above. The cells were counted at 72 h or 96 h after transfection using a Coulter Z2 Coulter Counter (Beckman Coulter, San Diego, CA, USA). In cell cycle studies, the cells were seeded (for cell numbers see Additional file 1: Table S2) on 6-well plates, transfected with KPNA7 or LUC siRNAs and analyzed 96 h after transfection. The cells were collected by trypsinization and suspended to 500 μL hypotonic staining buffer (0.1 mg/mL sodium citrate tribasic dehydrate, 0.03% Triton X-100, 50 μg/mL propidium iodide, 2 μg/mL RNase A) and the amount of propidium iodide incorporated was determined using flow cytometry (BD Accuri Cytometers, Ann Arbor, MI, USA). The cell cycle distributions were determined using the ModFit LT software (Verity Software House Inc., Topsham, ME, USA). All experiments were performed in six replicates and repeated at least twice.

Immunofluorescence assays

Immunofluorescence (IF) was used to assess the localization of γ-tubulin, different nuclear envelope proteins and formation of stress fibers. The cells were plated on coverslips on 24-well plates (for cell number see Additional file 1: Table S2) and the IF stainings were performed as previously described [29]. The following antibodies and dilutions were used: anti-lamin A/C 1:200 (ab8984, Abcam, Cambridge, UK), anti-lamin B1 1:500 (ab16048, Abcam), anti-NUP153 1:1000 (ab24700, Abcam), anti-γ-tubulin 1:500 (ab179503, Abcam), anti-phospho Myosin Light Chain 2 1:200 (#3674S, Cell Signaling Technology, Danvers, MA, USA), Alexa Fluor 568 Phalloidin 1:200 (Molecular Probes, Eugene, OR, USA) and Alexa Fluor secondary antibodies 1:200 (Molecular Probes). The samples were mounted in ProLong Antifade Gold reagent with DAPI (Molecular probes). The fluorescently labeled cells were photographed using the Zeiss Apotome or the Zeiss LSM 780 laser scanning confocal microscope (Zeiss, Oberkoche, Germany).

Quantification of the IF data

A total of 50 mitotic cells from γ-tubulin stained, siRNA treated cells were scored using the Zeiss Apotome (40X objective) and classified either as normal or abnormal based on the number of centrosomes and the structure of the mitotic spindle. The appearance of the nuclei was visually inspected from lamin A/C images obtained using the confocal microscope and a 40X objective. The nuclei were categorized as normal or aberrant and their number was determined from a minimum of six images. ImageJ software (US National Institute of Health, Bethesda, MD, USA) was used for the quantitation of the nuclear size and shape as well as nuclear aspects ratios in 50 randomly selected nuclei from samples stained with lamin A/C. In the case of NUP153 staining, ImageJ was used for the quantitation of the number of spots per nucleus.

Western blotting

Cell lysates were separated in a 7% (for NUP153) or 10% (for lamins) SDS-PAGE gel. The proteins were transferred onto polyvinylidene fluoride (PVDF) membrane (Roche) using a tank blotter (NUP153 western) or Trans-Blot SD semi-dry transfer cell (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was blocked with Blocking Reagent (Roche) in tris-buffered saline (TBS, 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) for 1 h at RT. After blocking, the membrane was probed with primary antibody diluted in 3% BSA in 0.05% TBS-Tween-20 (TBST) overnight at 4 °C and subsequently with HRP-conjugated IgG secondary antibody (Vector Laboratories, Burlingame, CA, USA) 1:8000 in 0.05% TBST for 1 h at RT. The protein bands were detected with Pierce™ ECL Plus Western Blotting Substrate (ThermoFischer Scientific, Waltham, MA, USA). The following antibodies and dilutions were used: anti-lamin A/C 1:500 (ab2811, Abcam), anti-lamin B1 1:1000 (ab16048, Abcam), anti-NUP153 1:1000 (ab24700, Abcam) and anti-β-Tubulin 1:20,000 (T7816, Sigma-Aldrich).

Statistical analyses

The Mann-Whitney test was used to statistically compare the means of the siKPNA7 and siLUC control groups.


KPNA7 is essential for pancreatic and breast cancer cell proliferation

We previously showed that amplification and subsequent overexpression of KPNA7 leads to promotion of cell growth in Hs700T and AsPC-1 pancreatic cancer cell lines [28]. To obtain a more comprehensive view on the functional role of this protein in cancer cells, we extended these studies to include pancreatic (MIA PaCa-2, SU.86.86) and breast (MCF-7, MDA-MB-231, T-47D) cancer cell lines without KPNA7 amplification and with varying levels of endogenous KPNA7 expression (Additional file 2: Figure S1). KPNA7 was silenced in these cell lines as well as the Hs700T cells with siRNAs leading to a minimum of 80% decrease in mRNA levels (Additional file 1: Table S3). As previously shown [28], the silencing resulted in a dramatic reduction of cell growth in Hs700T cells as compared to controls transfected with siRNAs targeting the firefly luciferase (LUC) gene (Fig. 1a). Likewise, the other pancreatic and breast cancer cell lines exhibited statistically significant decreases in proliferation after KPNA7 knock-down (Fig. 1a, b). In fact, there was a minimal or no difference in Hs700T and T-47D cell numbers between the 72 h and 96 h time points after transfection (Additional file 3: Figure S2A) indicating that KPNA7 silencing leads to an actual growth arrest as cell numbers do not change after 72 h. qRT-PCR was used to confirm the KPNA7 knock-down in all time points (Additional file 3: Figure S2B).
Fig. 1
Fig. 1

Silencing of KPNA7 inhibits cell proliferation in cells with endogenous KPNA7 expression. KPNA7 was silenced with siRNAs in (a) pancreatic and (b) breast cancer cell lines with different levels of endogenous KPNA7 expression, as well as in (c) KPNA7-negative cell lines. A siRNA targeting the firefly luciferase gene (LUC) was used as a control. Mean cell numbers (± SD of six replicates) were determined 72 or 96 h post-transfection and normalized to the mean of siLUC control of each cell line. The silencing efficiencies were verified in each case with qRT-PCR and are shown in Additional file 1: Table S3. The experiments were repeated at least twice and data from one representative experiment is shown. *p < 0.05, **p < 0.01

To confirm the specificity of the observed growth effect, the KPNA7 siRNAs were also transfected into both normal (hTERT-HPNE) and cancerous (MDA-MB-453) cells that completely lack KPNA7 expression (Additional file 2: Figure S1) and no changes in cell growth were observed (Fig. 1c). Since the efficacy of the KPNA7 siRNAs cannot be measured in these cells, parallel transfections with siRNAs against the SMAD5 gene were performed and led to a 70% reduction in mRNA level, thus indicating that the experimental conditions were appropriate. To evaluate the possible mechanisms behind the growth inhibition phenotype, cell cycle profiles were determined in one breast and one pancreatic cancer cell line (T-47D and MIA PaCa-2, respectively) 96 h after transfection with KPNA7 and LUC control siRNAs. These analyses revealed that KPNA7 inhibition resulted in a diminished fraction of proliferating S-phase cells, with a concomitant increase in G2-phase cells (Fig. 2). The fraction of sub-G1 cells was not altered (data not shown). These results are in agreement with our previous data on Hs700T cells [28].
Fig. 2
Fig. 2

KPNA7 depletion results in reduced number of S-phase cells. The cell cycle distributions were analyzed using flow cytometry 96 h after transfection of siRNAs against KPNA7 or LUC control gene. The experiment was repeated at least twice. The mean and SD of six replicates from a representative experiment are shown.*p < 0.05, **p < 0.01

Correct assembly of the mitotic spindle is affected by KPNA7 depletion

The growth arrest phenotype and altered cell cycle distributions of siKPNA7-treated cells led us to hypothesize that mitosis is disturbed in these cells. To address this issue, we studied the organization of centrosomes by staining their major structural component γ-tubulin, again in one pancreatic and one breast cancer cell line 96 h after transfection with KPNA7 and LUC control siRNAs. Unfortunately, the MIA Paca-2 cells turned out to grow in thick colonies partially on top of each other and had very dense nuclei and thus they were hard to image properly. Therefore, the Hs700T and T-47D cells were used these and all subsequent experiments. The number of centrosomes and the structure of the mitotic spindles was normal, with two centrosomes at the opposite ends of the cell and chromatin aligned correctly in the middle of the nucleus, in 100% and 98% of the mitotic siLUC transfected Hs700T and T-47D control cells, respectively (Fig. 3). In contrast, after KPNA7 silencing, 18% of mitotic Hs700T and 20% of mitotic T-47D cells harbored an abnormal number of centrosomes (Fig. 3). Typically, three to four centrosomes were observed, leading to distortion of the mitotic spindle and subsequent aberrant alignment of the chromatin.
Fig. 3
Fig. 3

Mitotic KPNA7-silenced cells exhibit aberrant number of centrosomes and an abnormal organization of the mitotic spindle. a Hs700T pancreatic cancer cells and (b) T-47D breast cancer cells were transfected with either KPNA7 or control LUC siRNA and γ-tubulin (green) was immunofluorescently labeled 96 h later. Nuclei were counterstained with DAPI (blue)

KPNA7 silencing results in distinct changes in nuclear morphology

Based on the DAPI-staining in the experiments described above, we noted that the KPNA7-silenced interphase cells had aberrant nuclear shape. To better visualize this effect, the cells were stained for lamin A/C, the major component of the nuclear lamina, revealing distinct lobular nuclear morphology in Hs700T cells (Fig. 4a). The quantitation of the number of normal vs. aberrant nuclei showed a dramatic increase in the fraction of abnormal nuclei from 17% in the control cells to 86% in the KPNA7-silenced cells (p < 0.01, Fig. 4b). The analysis of nuclear size and shape showed that the siKPNA7-treated Hs700T cells had significantly larger nuclei than the control cells (p < 0.01, Fig. 4f). The aspect ratio (calculated as indicated in Additional file 4: Figure S3 both in XY and YZ dimensions) of the nuclei in XY dimension was not affected, but a significant increase in YZ aspect ratio was observed (p < 0.005, Fig. 4f). These data indicate that in Hs700T cells KPNA7 depletion leads to the flattening of the nuclei, which was also visible in the cross-sectional view of the nuclei (Fig. 4a). In T-47D cells, KPNA7 depletion resulted in an elongated, distorted shape of the nuclei (Fig. 4c). Again, the number of aberrant nuclei was significantly increased from 16% in the control cells to over 70% in the KPNA7-silenced cells (p < 0.01, Fig. 4d). A small trend towards enlarged nuclear area and YZ aspect ratio was observed while the XY aspect ratio was significantly increased (Fig. 4g), thus providing quantitative confirmation on the elongation of the nuclei. Western blot analysis of the amount of lamin A/C protein showed no major changes in Hs700T cells but a noticeable decrease in T-47D cells after KPNA7 silencing (Fig. 5a).
Fig. 4
Fig. 4

KPNA7 is vital for the maintenance of proper nuclear morphology. a Hs700T pancreatic cancer cells and (c) T-47D breast cancer cells were treated with control (LUC) or KPNA7 siRNA and stained with lamin A/C antibody (green) 96 h post-transfection. The nuclei were counterstained with DAPI (blue). White squares indicate an individual cell for which an enlarged image is shown and white vertical lines pinpoint the location of which a cross-section of the nucleus is illustrated. The percentages of normal vs. aberrant nuclei were determined for (b) Hs700T and (d) T-47D cells from a minimum of six microscopic images. The mean and SD of the replicates are shown. e, f The nuclear area, XY aspect ratio and YZ aspect ratio were determined from 50 nuclei using the ImageJ software. The median is indicated with a horizontal line. **p < 0.01, ***p < 0.005

Fig. 5
Fig. 5

KPNA7 depletion induces alterations in the amounts of lamin proteins. Hs700T and T-47D cells were treated with control or KPNA7 siRNA and Western blotting performed 96 h after transfection with (a) lamin A/C or (b) lamin B1 antibodies. Tubulin was used as a loading control. The expression levels were quantitated using ImageJ software and were normalized against the tubulin loading control. The figures indicate relative protein expression levels for the siKPNA7 transfected cells as compared to the corresponding siLUC controls

To further assess the impact of KPNA7 depletion on nuclear structure, immunofluorescent staining of lamin B1, another major component of the nuclear lamina, was performed and unveiled radical reorganization and folding of the protein into the lobules of the nuclei of Hs700T and T-47D cells (Fig. 6a and b). The flattening of the Hs700T nuclei in the siKPNA7-treated cells was again clearly visible. Interestingly, Western blotting showed that the amount of lamin B1 protein was clearly increased in the siKPNA7-treated Hs700T cells compared to the corresponding controls whereas no alterations were seen in T-47D cells (Fig. 5b). To evaluate whether the alterations in nuclear shape are caused by the activation of contractility of the actin stress fibers, phosphorylated myosin light chain II (pMLCII) was immunofluorescently labeled but revealed no radical changes between the control and siKPNA7-treated cells in either Hs700T or T-47D cell line (Additional file 5: Figure S4).
Fig. 6
Fig. 6

KPNA7 silencing causes rearrangement of lamin proteins. a Hs700T and (b) T-47D cells were treated with control or KPNA7 siRNA and lamin B1 (green) was immunofluorescently labeled 96 h post-transfection. The nuclei were counterstained with DAPI (blue). The white squares indicate an individual cell for which an enlarged image is shown and the white vertical lines pinpoint the spot for which a cross-section of the nucleus is illustrated

Both the A- and B-type lamins have been shown to interact with nucleoporin 153 (NUP153) [30], one of the components of the inner ring of the NPC [31]. Cells depleted of NUP153 exhibit decreased proliferation and G1 arrest of the cell cycle, and NUP153 has also been implicated in the proper organization of nuclear lamina [31]. Immunofluorescent staining of NUP153 was carried out to evaluate whether KPNA7 silencing also influences the number or localization of the NPCs (Additional file 6: Figure S5A,C). Quantitative analysis indicated that the KPNA7 silenced Hs700T cells harbored slightly more NUP153 puncta per 100 μm2 than the control cells (Additional file 6: Figure S5B). The distribution of NUP153 spots between the apical and basal sides of the cells was not affected (data not shown). In T-47D, there were no distinct differences in NUP153 staining patterns between the siKPNA7 transfected and the control cells (Additional file 6: Figure S5B). Western blot analysis of the NUP153 protein levels revealed no alterations in the cellular amount of the protein in either cell line (Additional file 6: Figure S5D).


The complex network of proteins comprising the nuclear transport machinery is a critical player in maintaining the proper function of eukaryotic cells. In addition to nuclear transport, these proteins also contribute to other key cellular processes, such as the regulation of cell division [18, 19]. Changes in the functions of the transport proteins, e.g. due to altered expression levels, may thus lead to a variety of cellular defects, with cancer being an ultimate example [9].

In an earlier study, we showed that KPNA7 is an important regulator of pancreatic cancer cell growth in cell lines harboring amplification and high-level overexpression of the gene [28]. Moreover, lower levels of KPNA7 expression was detected in cancer cells without amplification whereas no or very low level expression expression was found in normal adult tissues with the exception of ovary and trachea [28], indicating re-activation of the gene in cancer cells. This led us to question whether low level KPNA7 expression also confers a growth benefit to cancer cells. The present study demonstrates that KPNA7 knock-down consistently decreased cell growth in all cell lines regardless of the endogenous expression level, although the most drastic effect was indeed seen in Hs700T cells with the highest KPNA7 expression. Furthermore, our data demonstrate that KPNA7 depletion results in a genuine growth arrest, as the knock-down cells exhibited minimal or no proliferation between 72 h and 96 h post-transfection. These results suggest that even a low amount of KPNA7 yields a growth advantage to cancer cells. In addition, the growth inhibition phenotype was detected both in pancreatic and breast cancer cell lines, indicating that the role of KPNA7 is not limited to pancreatic cancer. A similar growth regulatory function has been previously established for KPNA2, which is the closest relative of KPNA7 and is known to promote cell proliferation in many malignancies [16, 3234]. KPNA7 inhibition also led to alterations in the cell cycle, most notably manifesting as decreased fraction of proliferating S-phase cells, thereby partly explaining the growth defects. This finding is in accordance with our previous data that highlighted proteins participating in cell cycle regulation as KPNA7 cargo candidates [35]. It is thus plausible that the growth inhibiting effects of KPNA7 silencing are caused by diminished transport of cell cycle regulators to the nucleus.

The growth-promoting role and the expression pattern of KPNA7 makes it an interesting target for the development of cancer therapies. Inhibitors against KPNB1 and Exportin-1, a nuclear export factor of the karyopherin superfamily, have been tested in different cancers in clinical trials [36]. However, their development has been hindered by toxicities [36], probably due to their ubiquitous expression and essential function in healthy tissues. The targeting of KPNA7 would avoid this problem as its expression is in the current light mainly limited to cancer. On the other hand, the high conservation of the KPNA family members might provide an obstacle for drug development by creating unspecific effects. As Kelley et al. reported, KPNA7 is the most divergent member of the family [23] and might hence represent the most suitable drug target among the KPNAs. In addition, recent computational analysis implicated KPNA7 as a potential biomarker for pancreatic cancer [37].

Immunofluorescent analysis of γ-tubulin revealed an abnormal number of centrosomes and mitotic spindle poles in a notable fraction of the siKPNA7-treated cells, with chromatin being pulled by three or more mitotic spindles towards as many centrosomes. Mislocalization of the GEF Ran guanine nucleotide exchange factor (RCC1), which has a key role in maintaining the appropriate Ran-GTP gradient, is also known to result in multipolar spindles [20]. RCC1 has an NLS and it has been shown to be transported into the nucleus by the KPNA3 and KPNB1 complex [20]. Our previous study pinpointed the GEF Ran-binding protein 10 (RANBP10) as well as multiple other microtubule-associated proteins as putative KPNA7 cargos [35] and thus their diminished transport to the nucleus in KPNA7 silenced cells may contribute to aberrant spindle formation. However, KPNA7 itself has been shown to localize to the spindle structures in murine cells [25], suggesting that it may also directly influence spindle formation. Moreover, KPNB1 was demonstrated to regulate the formation of the spindle via its importin alpha binding (IAB) domain, further supporting the possible role of karyopherins in the regulation of spindle formation [38].

KPNA7 depletion also induced distinct changes in the nuclear morphology in both Hs700T pancreatic and T-47D breast cancer cells. The nuclear lobulation does not seem to be fatal for the cells, but may explain the growth arrest observed. Changes in nuclear shape are usually attributed to different lamin proteins, i.e. intermediate filaments that form the nuclear lamina scaffold adjacent to the inner nuclear membrane [39]. For example, mutations in lamin proteins have been linked to many diseases known as laminopathies, which are associated with altered nuclear structure and shape [40]. Lobulated nuclei, similar to those in KPNA7 depleted Hs700T cells, are seen in the Hutchinson–Gilford progeria syndrome (HGPS), which is caused by mutations in lamin A [41]. However, reduction in total amount of lamin B1 has been reported in HGPS [40] whereas we observed an increase in lamin B1 protein. Together these data indicate that the mechanisms behind the lobulation of nuclei are diverse and different alterations in lamin proteins contribute to this phenomenon.

Lamins A and C confer stiffness to the nuclei, stabilizing the nucleus against stress, whereas B-type lamins lend elasticity [42, 43]. The increased amount of lamin B1 in KPNA7 silenced Hs700T cells is thus likely to render the nuclear lamina more elastic. This point is supported by the increased nuclear area, the changed YZ aspect ratio of the nuclei, and the cross-sectional views of the lamin protein stainings, all suggesting that the Hs700T nuclei are flattened after the siKPNA7 treatment. In T-47D cells, no increase in lamin B1 was detected but lamin A/C amount was decreased. This might have a similar impact on nuclear rigidity as lamin B1 increase, since lamin A/C depleted cells show reduced nuclear stiffness [43, 44]. The nuclei of the T-47D cells are relatively flat to begin with, as evidenced by high YZ aspect ratios, possibly explaining why KPNA7 silencing did not induce similar flattening of the nuclei as seen in Hs700T but instead resulted in elongated, elliptical nuclear shape.

Loss of lamin B1 levels have been associated with cellular senescence, a potent tumor-suppressive mechanism that leads to an irreversible cell cycle exit, and the lamin B1 loss has also been suggested as a senescence-associated biomarker [45, 46]. For example, in WI-38 human lung embryonic fibroblast cells, silencing of lamin B1 induced premature senescence and, vice versa, the overexpression delayed the onset of senescence [47]. However, in other studies upregulation of lamin B1 has been linked with induction of senescence [47]. The current conclusion thus seems to be that the change in lamin B1 levels is not fully responsible for the senescence phenotype [46, 48]. This notion is in concert with our previous data [28] showing that the siKPNA7-treated Hs700T cells, despite the altered lamin B1 amount demonstrated here, do not exhibit senescence-like characteristics.

It is interesting that the majority (80%) of the siKPNA7-treated cells exhibited changes in nuclear morphology, whereas only 20% of the mitotic cells presented with aberrant multipolar spindles. Based on these observations one could conclude that the main impact of KPNA7 depletion is on lamins and nuclear morphology. Nuclear lamins have been shown to play a role in the formation of the mitotic spindle matrix [49], and hence the observed aberrant mitosis may be related to abnormal spindle formation due to the improper function of the lamins. However, our study does not provide solid evidence on the chronological sequence of events between the mitotic defects and altered nuclear morphology, or whether these phenomena are indeed mechanistically connected.


In this study, we demonstrate that the silencing of KPNA7, the least studied member of the karyopherin alpha family of nuclear transport proteins, leads to a distinct inhibition of pancreatic and breast cancer cell proliferation, in spite of the endogenous expression level. Our data also demonstrate that KPNA7 has a critical role in the regulation of mitosis through the proper organization of the mitotic spindle and acts in the maintenance of the nuclear envelope structure and nuclear morphology. These results shed new light on the function of KPNA7 in the regulation of cancer cell growth and the maintenance of nuclear envelope environment, and thereby further enhance our knowledge on the role of nuclear transfer proteins in cancer pathogenesis.





GTPase activating protein


Guanine nucleotide exchange factor


Hutchinson–Gilford progeria syndrome


Importin alpha binding domain

KPNA (2, 4, 7,): 

Karyopherin alpha (2, 4, 7)


Karyopherin beta 1


Firefly luciferase


Nuclear localization signal


Nuclear pore complex


Nucleoporin 153


Tumor suppressor protein 53


Phosphorylated myosin light chain II


Ran-binding protein 10


GTP-binding nuclear protein Ran


Ran guanine nucleotide exchange factor


Spindle assembly factor


small interfering RNA



We thank Ms. Kati Rouhento and Sanna Penkki, M.Sc for skillful assistance in this study. Tampere Imaging Facility is acknowledged for providing excellent imaging resources for this study.


This work was supported by the Academy of Finland (grants 251066 and 267471), Sigrid Jusélius Foundation, Pirkanmaa Cancer Society (to N.K.R.), Tampere Graduate Program in Biomedicine and Biotechnology (to E.M.V.), Jenny and Antti Wihuri Foundation (to E.M.V.) and The Cancer Society of Finland (to E.M.V).

Availability of data and materials


Authors’ contributions

EMV, NKR, TOI and AK. designed the research; EMV and NKR performed research and analyzed data; TOI provided insights to the interpretation of data; EMV. and NKR drafted the manuscript; TOI and AK provided critical revisions to the intellectual content. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note



Authors’ Affiliations

BioMediTech Institute and Faculty of Medicine and Life Sciences, University of Tampere, PL 100, 33014 Tampere, Finland
BioMediTech Institute and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, University of Tampere, PL 100, 33014 Tampere, Finland
Tampere Imaging Facility, BioMediTech Institute and Faculty of Medicine and Life Sciences, University of Tampere, PL 100, 33014 Tampere, Finland
Fimlab Laboratories, Biokatu 4, 33520 Tampere, Finland


  1. Mor A, White MA, Fontoura BMA. Nuclear trafficking in health and disease. Curr Opin Cell Biol. 2014;28:28–35.View ArticlePubMedGoogle Scholar
  2. Di Ventura B, Kuhlman B. Go in! Go out! Inducible control of nuclear localization. Curr Opin Chem Biol. 2016;34:62–71.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Knockenhauer K, Schwartz T. The nuclear pore complex as a flexible and dynamic gate. Cell. 2016;164:1162–71.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Terry LJ, Shows EB, Wente SR. Crossing the nuclear envelope: hierarchical regulation of nucleocytoplasmic transport. Science. 2007;318:1412–6.View ArticlePubMedGoogle Scholar
  6. Tran EJ, King MC, Corbett AH. Macromolecular transport between the nucleus and the cytoplasm: advances in mechanism and emerging links to disease. Biochim Biophys Acta. 1843;2014:2784–95.Google Scholar
  7. Stewart M. Molecular mechanism of the nuclear protein import cycle. Nat Rev Mol Cell Biol. 2007;8:195–208.View ArticlePubMedGoogle Scholar
  8. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4:106–17.View ArticlePubMedGoogle Scholar
  9. Faustino RS, Nelson TJ, Terzic A, Perez-Terzic C. Nuclear transport: target for therapy. Clin Pharmacol Ther. 2007;81:880–6.View ArticlePubMedGoogle Scholar
  10. Hung M, Link W. Protein localization in disease and therapy. J Cell Sci. 2011;124:3381–92.View ArticlePubMedGoogle Scholar
  11. Jeyasekharan AD, Liu Y, Hattori H, Pisupati V, Jonsdottir AB, Rajendra E, et al. A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat Struct Mol Biol. 2013;20:1191–8.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Lee K, Byun K, Hong W, Chuang HY, Pack CG, Bayarsaikhan E, et al. Proteome-wide discovery of mislocated proteins in cancer. Genome Res. 2013;23:1283–94.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992;89:7262–6.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Kim IS, Kim DH, Han SM, Chin MU, Nam HJ, Cho HP, et al. Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem. 2000;275:23139–45.View ArticlePubMedGoogle Scholar
  15. Christiansen A, Dyrskjøt L. The functional role of the novel biomarker karyopherin α 2 (KPNA2) in cancer. Cancer Lett. 2013;331:18–23.View ArticlePubMedGoogle Scholar
  16. Zhou LN, Tan Y, Li P, Zeng P, Chen MB, Tian Y, et al. Prognostic value of increased KPNA2 expression in some solid tumors: a systematic review and meta-analysis. Oncotarget. 2016;8:303–14.PubMed CentralGoogle Scholar
  17. Yang J, Lu C, Wei J, Guo Y, Liu W, Luo L, et al. Inhibition of KPNA4 attenuates prostate cancer metastasis. Oncogene. 2016;36:2868–78.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Mosammaparast N, Pemberton LF. Karyopherins: from nuclear-transport mediators to nuclear-function regulators. Trends Cell Biol. 2004;14:547–56.View ArticlePubMedGoogle Scholar
  19. Forbes DJ, Travesa A, Nord M, Bernis C. Nuclear transport factors: global regulation of mitosis. Curr Opin Cell Biol. 2015;35:78–90.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Clarke PR, Zhang C. Spatial and temporal coordination of mitosis by ran GTPase. Nat Rev Mol Cell Biol. 2008;9:464–77.View ArticlePubMedGoogle Scholar
  21. Hachet V, Köcher T, Wilm M, Mattaj IW. Importin α associates with membranes and participates in nuclear envelope assembly in vitro. EMBO J. 2004;23:1526–35.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Goldfarb DS, Corbett AH, Mason DA, Harreman MT, Adam SA. Importin alpha: a multipurpose nuclear-transport receptor. Trends Cell Biol. 2004;14:505–14.View ArticlePubMedGoogle Scholar
  23. Kelley JB, Talley AM, Spencer A, Gioeli D, Paschal BM. Karyopherin alpha7 (KPNA7), a divergent member of the importin alpha family of nuclear import receptors. BMC Cell Biol. 2010;11:63.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Tejomurtula J, Lee K, Tripurani SK, Smith GW, Yao J. Role of importin Alpha8, a new member of the importin alpha family of nuclear transport proteins, in early embryonic development in cattle. Biol Reprod. 2009;81:333–42.View ArticlePubMedGoogle Scholar
  25. Hu J, Wang F, Yuan Y, Zhu X, Wang Y, Zhang Y, et al. Novel importin-α family member Kpna7 is required for normal fertility and fecundity in the mouse. J Biol Chem. 2010;285:33113–22.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Wang X, Park KE, Koser S, Liu S, Magnani L, Cabot RA. KPNA7, an oocyte- and embryo-specific karyopherin alpha subtype, is required for porcine embryo development. Reprod Fertil Dev. 2012;24:382–91.View ArticlePubMedGoogle Scholar
  27. Laurila E, Savinainen K, Kuuselo R, Karhu R, Kallioniemi A. Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer. Genes Chromosomes Cancer. 2009;48:330–9.View ArticlePubMedGoogle Scholar
  28. Laurila E, Vuorinen E, Savinainen K, Rauhala H, Kallioniemi A. KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in vitro. Exp Cell Res. 2014;322:159–67.View ArticlePubMedGoogle Scholar
  29. TO I, Aires L, Herzog FA, Schwartlander R, Moeller J, Vogel V. Differential basal-to-apical accessibility of Lamin a/C epitopes in the nuclear lamina regulated by changes in cytoskeletal tension. Nat Mater. 2015;14:1252–61.View ArticleGoogle Scholar
  30. Al-Haboubi T, Shumaker DK, Köser J, Wehnert M, Fahrenkrog B. Distinct association of the nuclear pore protein Nup153 with A- and B-type lamins. Nucleus. 2011;2:500–9.View ArticlePubMedGoogle Scholar
  31. Zhou L, Panté N. The nucleoporin Nup153 maintains nuclear envelope architecture and is required for cell migration in tumor cells. FEBS Lett. 2010;584:3013–20.View ArticlePubMedGoogle Scholar
  32. Ma S, Zhao X. KPNA2 is a promising biomarker candidate for esophageal squamous cell carcinoma and correlates with cell proliferation. Oncol Rep. 2014;32:1631–7.View ArticlePubMedGoogle Scholar
  33. Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, et al. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. J Pathol. 2014;234:239–52.PubMedGoogle Scholar
  34. Umegaki-Arao N, Tamai K, Nimura K, Serada S, Naka T, Nakano H, et al. Karyopherin alpha2 is essential for rRNA transcription and protein synthesis in proliferative keratinocytes. PLoS One. 2013;8:e76416.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Vuorinen EM, Rajala NK, Rauhala HE, Nurminen AT, Hytönen VP, Kallioniemi A. Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth. Biochim Biophys Acta. 1863;2017:211–9.Google Scholar
  36. Mahipal A, Malafa M. Importins and exportins as therapeutic targets in cancer. Pharmacol Ther. 2016;164:135–43.View ArticlePubMedGoogle Scholar
  37. Shen S, Gui T, Ma C. Identification of molecular biomarkers for pancreatic cancer with mRMR shortest path method. Oncotarget. 2017;8:41432–9.PubMedPubMed CentralGoogle Scholar
  38. Roscioli E, Di Francesco L, Bolognesi A, Giubettini M, Orlando S, Harel A, et al. Importin-β negatively regulates multiple aspects of mitosis including RANGAP1 recruitment to kinetochores. J Cell Biol. 2012;196:435–50.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Gruenbaum Y, Foisner R. Lamins: nuclear intermediate filament proteins with fundamental functions in nuclear mechanics and genome regulation. Annu Rev Biochem. 2015;84:131–64.View ArticlePubMedGoogle Scholar
  40. Schreiber K, Kennedy B. When Lamins go bad: nuclear structure and disease. Cell. 2013;152:1365–75.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Taimen P, Pfleghaar K, Shimi T, Möller D, Ben-Harush K, Erdos MR, et al. A progeria mutation reveals functions for Lamin a in nuclear assembly, architecture, and chromosome organization. Proc Natl Acad Sci U S A. 2009;106:20788–93.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Osmanagic-Myers S, Dechat T, Foisner R. Lamins at the crossroads of mechanosignaling. Genes Dev. 2015;29:225–37.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Lammerding J, Fong LG, Ji JY, Reue K, Stewart CL, Young SG, et al. Lamins a and C but not Lamin B1 regulate nuclear mechanics. J Biol Chem. 2006;281:25768–80.View ArticlePubMedGoogle Scholar
  45. Freund A, Laberge R, Demaria M, Campisi J. Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell. 2012;23:2066–75.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Chojnowski A, Ong PF, Dreesen O. Nuclear lamina remodelling and its implications for human disease. Cell Tissue Res. 2015;360:621–31.View ArticlePubMedGoogle Scholar
  47. Shimi T, Butin-Israeli V, Adam SA, Hamanaka RB, Goldman AE, Lucas CA, et al. The role of nuclear Lamin B1 in cell proliferation and senescence. Genes Dev. 2011;25:2579–93.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Hutchison CJ. B-type lamins in health and disease. Semin Cell Dev Biol. 2014;29:158–63.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Dechat T, Adam SA, Taimen P, Shimi T, Goldman RD. Nuclear Lamins. Cold Spring Harb Perspect Biol. 2010;2:a000547.View ArticlePubMedPubMed CentralGoogle Scholar